Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

Fig. 2

Immunomodulatory and anti-angiogenic effects of CR6086 in vitro. CR6086 inhibition of interleukin (IL)-6 (a) and vascular endothelial growth factor (VEGF) (b) gene expression in THP-1 cells differentiated to macrophages. CR6086 inhibition of IL-23 release from dendritic cells (c) and IL-17 release from Th17 cells (d) compared with naproxen. Results are expressed as mean percentage effect/inhibition ± SD of independent experiments performed in triplicate. *P < 0.05 and **P < 0.01 vs control by one-way analysis of variance with Tukey-Kramer multiple comparisons test. LPS Lipopolysaccharide, PGE 2 Prostaglandin E2, T H 17 T-helper type 17 cell

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us